Author + information
- Manabu Ogita,
- Katsumi Miyauchi,
- Meizi Jiang,
- Shuta Tsuboi,
- Ryo Naito,
- Hirokazu Konishi,
- Tomotaka Dohi,
- Takatoshi Kasai,
- Hideaki Bujo and
- Hiroyuki Daida
Restenosis after vascular intervention remains major clinical problems. LR11 is a novel marker of intimal smooth muscle cell (SMC) proliferation. The aim of the present study is to evaluate the clinical significance of circulating LR11 after coronary stenting and the role of LR11 in regulating vascular smooth muscle cell after vascular injury in animal model.
Methods and Results
The circulating soluble LR11 levels were prospectively measured (pre-procedure, on days 14, 60 and 240 after the procedure in 109 consecutive stable angina pectoris (mean age 62.3 ± 13.0 years; male 78.0%) patients successfully treated with percutaneous coronary intervention. Concentration of serum LR11 was measured by sandwich enzyme-linked immunosorbent assay method. Circulating sLR11 was significantly increased on days 14 and 60 as compared with pre-procedure (10.53 ± 2.94 vs. 12.90 ± 3.62 vs. 12.77 ± 4.10, p < 0.001) and declined substantially thereafter, which was consistent with cuff injury model in mice (FigA). Circulating sLR11 levels was associated with the LR11 and myosin expression levels of intimal SMCs after arterial injury in mice.
Circulating sLR11 is significantly elevated in response to vascular injury after the procedure. LR11 might be a potential biomarker for vascular injury after coronary intervention.
Poster Sessions, Expo North
Saturday, March 09, 2013, 10:00 a.m.-10:45 a.m.
Session Title: Chronic CAD: Mechanisms of Repair
Abstract Category: 9. Chronic CAD/Stable Ischemic Heart Disease: Basic
Presentation Number: 1109-64
- 2013 American College of Cardiology Foundation